HYPER-MASTIC: AN ORIGINAL SCIENTIFIC RESEARCH PROJECT HEADED BY IASIS PHARMA WITH THE PARTICIPATION OF A CONSORTIUM OF ACADEMIC AND CORPORATE ORGANIZATIONS

08/11/2021|All articles, Company news, Exploiting the gifts of Greek nature, Research & development, Research and development projects|

www.hyper-mastic.eu - Facebook: Hyper-Mastic Focusing on the study of the Greek nature, IASIS PHARMA is glad to announce the launch of HYPER-MASTIC, a scientific research project to be carried out in cooperation with a team of Academic and Corporate entities. The project members are: - IASIS PHARMA a pharmaceutical industry - Chios Gum Mastic Growers Association [...]

IASIS PHARMA PARTICIPATION IN THE 41st PANHELLENIC GASTROENTEROLOGICAL CONFERENCE

29/10/2021|All articles, Press Room|

21 - 24/10/2021, Hotel Du Lac, Ioanina, Greece IASIS PHARMA participated (with sponsorship) in the 41st Panhellenic Gastroenterological Conference, held under the auspices of the Hellenic Gastroenterological Society (EGE), at Hotel Du Lac in Ioannina, on 21 - 24/10/2021. IASIS PHARMA presented the unique herbal medicine [E.M.A. 2015], mastiha var.Chia®caps, which can be used against [...]

IASIS PHARMA PARTICIPATION IN THE 2021 PANHELLENIC CONGRESS OF THE HELLENIC OSTEOPOROSIS FOUNDATION

23/09/2021|All articles, Press Room|

Divani Meteora Hotel Kalampaka, 17-19 / 09/2021 IASIS PHARMA is pleased to announce its participation with physical presence in the hybrid Panhellenic Congress of the Hellenic Osteoporosis Foundation, which took place on September 17-19, at Divani Meteora Hotel in Kalampaka. At IASIS PHARMA exhibition stand, the following products were presented: COVED®: Alendronic Acid 70mg / [...]

NEW PRODUCT LAUNCH: ETROZAC®

20/09/2021|All articles, Product launches|

IASIS PHARMA is pleased to announce the release of its new product ETROZAC®. ETROZAC® active substance is etoricoxib which is a selective cox-2 inhibitor. ETROZAC® is indicated for the relief of the symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis and the pain and symptoms of inflammation associated with Acute Gout. ETROZAC® is indicated for the [...]

NEW PRODUCT LAUNCH: Rami – Amlo plus®

17/09/2021|All articles, Product launches|

IASIS PHARMA is pleased to announce the release of the new product Rami – Amlo plus® Rami – Amlo plus® is an original (prototype) fixed dose combination of Ramipril – Amlodipine -Hydrochlorothiazide Rami – Amlo plus® is indicated for the treatment of hypertension. Available in packs of 30 capsules, in a wide dosage range: Rami [...]

IASIS PHARMA PARTICIPATION IN THE 4th PANHELLENIC CONGRESS OF S.S.D.A.D.

07/09/2021|All articles, Press Room|

Grand Hyatt Hotel, Athens, 2 - 5/09/2021 IASIS PHARMA participated with physical presence in the 4th hybrid Panhellenic Congress under the title: “Dermatological diseases 2021: Past, present and future” which was held on September 2-5 at Grand Hyatt Hotel Athens. At IASIS PHARMA exhibition stand, two of its major Dermatological products were presented: Modiwart® / [...]

IASIS PHARMA PARTICIPATION IN THE 33RD PANHELLENIC CONGRESS OF FAMILY MEDICINE

07/09/2021|All articles, Press Room|

RAMANDA PLAZA THRAKI, Alexandroupoli, 2-5/09/2021 IASIS PHARMA with a high sense of responsibility and in response to the COVID-19 crisis peculiarities, successfully participated with physical presence in the 33rd Panhellenic Congress of Greek Association of General Practice, thus expressing its practical interest and support to the medical community. IASIS PHARMA has a wide portfolio of [...]

R&D COMPANY FOUNDATION – NATURAL PRODUCTS COMPETENCE CENTER (NPCC) – IASIS PHARMA JOINT VENTURE

03/09/2021|All articles, Company news, Exploiting the gifts of Greek nature, Research & development|

IASIS PHARMA expands its activities focusing on Greek nature, collaborating in the establishment of Natural Products Competence Center (NPCC). NPCC is a Collaborative Innovation Formation, with the participation of 15 partners from the academic and business sectors. The project is coordinated by the Laboratory for the Utilization of Bioactive Natural Products (Department of Pharmacy, National [...]

IASIS PHARMA PARTICIPATION IN THE SPRING MEETING OF EDAE 2021

14/06/2021|All articles, Press Room|

ATHENS CONCERT HALL, 11 - 12/06/2021 Despite COVID-19 pandemic predicaments, IASIS PHARMA successfully participated in the Annual Spring Day Hybrid (both with physical and in webinar form) Conference, held by the Hellenic Society of Dermatology and Venereology, which took place on June 11 – 12 at Athens Concert Hall - International Conference Centre. IASIS PHARMA participated actively in the event, [...]

CHIOS MASTIC RESEARCH & DEVELOPMENT CENTER: AIR CONDITIONING & VENTILATION SYSTEMS COMPLETED

26/05/2021|All articles, Company news|

Construction activities at the Chios Mastic Research and Development Center continue at an intensive pace, most recent being the completion of the air conditioning & ventilation systems. Since the project started, the basic intention of the facilities’ design was its typological differentiation from a "typical" industrial facility, but at the same time meeting pharmaceutical industry [...]

Load More Posts